Marc Dror Michaelson
Impact in
- Pulmonary and Respiratory Medicine top 0.05%
- Renal cell carcinoma treatment
- Cancer Research top 0.2%
- Cancer Genomics and Diagnostics
- Cancer, Hypoxia, and Metabolism
Papers in
-
- Renal cell carcinoma treatment 81
- Prostate Cancer Treatment and Research 18
- Oncology 33
- Bone health and treatments 9
- Cancer Immunotherapy and Biomarkers 8
- Co-authors
- Robert John Motzer (31 shared papers)Sindy T. Kim (9 shared papers)Thomas E. Hutson (16 shared papers)Ronald M. Bukowski (9 shared papers)Robert A. Figlin (16 shared papers)Charles M. Baum (5 shared papers)Sylvie Négrier (10 shared papers)Piotr Tomczak (5 shared papers)
- Journals
- Journal of the National Comprehensive Cancer Network (15 papers)Annals of Oncology (15 papers)Journal of Clinical Oncology (12 papers)Cancer (9 papers)European Journal of Cancer (8 papers)
- Partner nations
- United StatesUnited KingdomCanada
In The Last Decade
Marc Dror Michaelson
152 papers receiving 21.7k citations
Marc Dror Michaelson's Hit Papers
Peers
Comparison fields: 5 of 135
- Pulmonary and Respiratory Medicine 13.8k
- Cancer Research 5.2k
- Oncology 5.1k
- Molecular Biology 8.0k
- Surgery 2.0k
Countries citing papers authored by Marc Dror Michaelson
This map shows the geographic impact of Marc Dror Michaelson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Dror Michaelson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Dror Michaelson more than expected).
Fields of papers citing papers by Marc Dror Michaelson
This network shows the impact of papers produced by Marc Dror Michaelson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Dror Michaelson. The network helps show where Marc Dror Michaelson may publish in the future.
Co-authors
The 25 scholars most cited alongside Marc Dror Michaelson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 154 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma Hit paper breakdown → | 2007 | 4810 |
| 2 | Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma Hit paper breakdown → | 2009 | 1843 |
| 3 | Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Hit paper breakdown → | 2011 | 1544 |
| 4 | Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma Hit paper breakdown → | 2005 | 1379 |
| 5 | Sunitinib in Patients With Metastatic Renal Cell Carcinoma Hit paper breakdown → | 2006 | 1025 |
| 6 | Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial Hit paper breakdown → | 2015 | 779 |
| 7 | Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial Hit paper breakdown → | 2013 | 610 |
| 8 | Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial Hit paper breakdown → | 2017 | 598 |
| 9 | Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology Hit paper breakdown → | 2022 | 472 |
| 10 | Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology Hit paper breakdown → | 2017 | 460 |
| 11 | Kidney Cancer Hit paper breakdown → | 2009 | 403 |
| 12 | 2007 | 376 | |
| 13 | 2008 | 340 | |
| 14 | Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update Hit paper breakdown → | 2018 | 306 |
| 15 | Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience Hit paper breakdown → | 2017 | 292 |
| 16 | 2007 | 273 | |
| 17 | 2007 | 259 | |
| 18 | 2020 | 238 | |
| 19 | Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis Hit paper breakdown → | 2021 | 236 |
| 20 | 2015 | 201 |
About Marc Dror Michaelson
Marc Dror Michaelson is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Molecular Biology and Surgery, having authored 154 papers that have together received 22.3k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (81 papers), Renal and related cancers (23 papers), Prostate Cancer Treatment and Research (18 papers), Bladder and Urothelial Cancer Treatments (14 papers), Cancer Genomics and Diagnostics (11 papers), Bone health and treatments (9 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Economic and Financial Impacts of Cancer (7 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (13.8k citations), Cancer Research (5.2k citations), Oncology (5.1k citations), Molecular Biology (8.0k citations) and Surgery (2.0k citations). Marc Dror Michaelson has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Robert John Motzer, Sindy T. Kim, Thomas E. Hutson, Ronald M. Bukowski, Robert A. Figlin, Charles M. Baum, Sylvie Négrier, Piotr Tomczak, Stéphane Marie. Oudard and Isan Chen. Their work appears in journals such as Journal of the National Comprehensive Cancer Network, Annals of Oncology, Journal of Clinical Oncology, Cancer and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.